By Dipo Olowookere
The international humanitarian organisation Doctors without Borders (MSF) has launched a large scale measles vaccination campaign in the capital of Guinea, Conakry, together with the Guinean ministry of Health.
Since the beginning of the year there have been 3468 confirmed cases and 14 deaths dues to measles in Guinea. Conakry and Nzérékoré are the most affected districts.
Routine vaccination in Guinea was drastically reduced during the 2014-2015 Ebola epidemic, both because most resources and attention were geared towards the management of Ebola and, mainly, due to fear: people stayed away from health facilities, vaccination activities were suspended because infection risks; this left thousands of young children unprotected against easily preventable diseases.
A nation-wide vaccination campaign was organised by authorities one year ago to vaccinate the children who had not received their shots (MSF did not participate to this campaign). Despite this catch up effort, a measles epidemic was declared on February 8th 2017.
“The fact that a new epidemic occurs barely a year after a massive vaccination campaign is a worrying sign of the weakness of health care in Guinea”, deplores Ibrahim Diallo, MSF’s representative in Guinea. “Major problems remain in the health system, undermining its capacity to prevent and respond to outbreaks effectively and timely.”
After the devastating Ebola epidemic that killed over 11.000 people and severely affected the health systems of the three most affected countries (Guinea, Sierra Leone and Liberia), the WHO and leading public health experts insisted on the importance of rebuilding responsive health systems in the three countries, equipping and supporting them to better manage similar or new health crises.
According to the UN body in charge of Ebola response, only 18 percent of the funds disbursed to support the countries’ during Ebola were meant for recovery. International donor commitments to health systems strengthening has focused on improving disease surveillance to assure early detection and response of outbreaks, such as Ebola.
International donor commitments to health systems strengthening has focused on improving disease surveillance to assure early detection and response of outbreaks, such as Ebola.
However, today, faced with a large outbreak of measles, MSF (in Conakry) and Alima (in Nzérokoré district) up to now are the NGOs providing support to the Ministry of Health for the vaccination campaign in the worst affected districts. WHO and UNICEF have pledged support to other affected districts across the country, which is still under discussion.
“If Ebola was a wakeup call, since then the world seems to have fallen back asleep. As shown by this measles outbreak, the concrete impact of the promises of funding, support and training made during and after the Ebola crisis still remains to be felt by ordinary Guineans,” says Dr Mit Philips, MSF’s Health Policy Analyst. “Access to good healthcare was clearly lacking before Ebola struck, and the country is still facing today the same problems that it was facing then, largely alone, in spite of the international public commitments to build better and more responsive health systems”.
To contain the measles epidemic, MSF, with the Ministry of Health in Conakry, is mobilising 126 teams of 13 people, spread out across 164 vaccination sites in the city of 3 million people.
All children from 6 months up to 10 years old will be vaccinated. MSF also supports 30 health centres in Conakry to care for children suffering from mild cases of measles, as well as the referral centre where severe cases are hospitalised.
Streamlining and Increasing Pharmacy Inventory Workflow
Pharmacies are an essential part of the healthcare system. However, managing pharmacy inventory is difficult for pharmacists due to the complexity of tracking stock levels and expiration dates. Streamlining and increasing pharmacy inventory workflows help make this process more efficient. Here are some tips that can help pharmacies maximize their inventory workflow.
Use Pharmacy Inventory Solutions
With comprehensive pharmacy inventory solutions, pharmacists will keep track of all their supplies in an organized manner. Such solutions offer a wide range of features to help streamline the inventory process and make it easier for pharmacies to manage their inventory. Features such as automated order fulfilment, real-time stock visibility, and streamlined processes help reduce mistakes and save time.
Automate Reordering Processes
Automating the reordering process is another way to increase pharmacy workflow efficiency. By automating the ordering process, pharmacies no longer have to manually place orders or check on availability when items are out of stock. This allows pharmacists to focus on more important tasks instead of wasting time on mundane administrative chores. Additionally, automated reordering systems allow better tracking and forecasting of inventory needs.
Implement Barcode Scanning
A barcode scanner is very helpful for pharmacies in tracking inventory levels and identifying items quickly. This helps to reduce errors and streamline the process of counting inventory. Barcode scanners are also used with automated reordering solutions to ensure orders are placed accurately and on time.
Additionally, barcode scanners track expiration dates and alert staff when items need to be restocked or thrown away. This way, pharmacists don’t have to worry about expired products on the shelves.
Utilize Analytics Tools
Analytics tools provide pharmacies with valuable insight into their inventory workflow and help them identify areas where they may need improvements. With analytics, pharmacists can track trends in sales data and stock levels and monitor customer buying patterns. That allows them to anticipate customer needs better and adjust their ordering processes accordingly. It also helps pharmacists track certain items’ performance and decide what products best suit their business model.
Proper Employee Training
Employees are the foundation of any successful business, and proper employee training is essential for ensuring that pharmacy inventory workflow processes are efficient. Pharmacists should ensure that their staff is properly trained to use the various systems and tools. Training should also include tips on how to keep up with stock levels, expiration dates, and drug interactions. With the right training, employees help prevent errors and save time when managing the pharmacy’s inventory.
Invest in Quality Control
Pharmacists should also invest in quality control processes to ensure that their inventory remains updated. Quality control procedures help identify discrepancies or issues with the inventory and alert staff when problems occur. This helps prevent expired items from reaching customers or mistakes made with orders. Quality control processes also help pharmacies save money by preventing waste and ensuring that items are ordered in the right quantities.
Focus on Customer Service
Finally, pharmacies should focus on providing excellent customer service. This involves ensuring that customers have accurate information about their medications and being available whenever they need help.
Pharmacists should also take the time to answer customer questions and address any concerns they may have. This way, pharmacists ensure that customers leave satisfied, leading to better sales and repeat business.
Implementing the strategies mentioned above helps streamline and increase pharmacy inventory workflow. Automating reordering processes, utilizing analytics tools, investing in quality control, and focusing on customer service are great ways to improve efficiency and increase profits. Pharmacies will operate more smoothly and efficiently with the right systems and processes.
Research Shows Interorganisational Deals Boost Drug Discovery, Innovation
By Adedapo Adesanya
In a recent study published in the journal Drug Discovery Today, a team of scientists at Ritsumeikan University in Japan analysed the changing trends in pharmaceutical industries to spotlight the role of interorganisational collaborations in promoting drug discovery and innovation.
Discovering new drugs has become increasingly rare for independent large pharmaceutical companies in recent times. With numbers showing that almost 60 per cent of new drugs are discovered through mergers and acquisitions and drug licensing.
Now, the university researchers shed light on the recent trends of spinouts from academia and investments in the US and Europe, foreshadowing a promising shift in the industry’s interorganisational deal networks to improve research and development productivity in the future.
“It is a challenging feat to launch a new drug in the market, given the low probability of success during the research and development (R&D) phase and the high costs involved. In recent times, industry trends in external innovation for drug discovery are rapidly changing. With an improved understanding of disease biology, decision-making can be more streamlined through the effective use of scientific information,” a statement made available to Business Post said.
Led by Associate Professor Kota Kodama of Ritsumeikan University, the team is uncovering how the trends in interorganisational deals in the pharmaceutical industry are changing to improve R&D productivity and drug discovery.
“The network structure of innovation creation in the pharmaceutical industry has changed with the increasing emergence of start-up companies spinning out from academia and research institutions as players in the source of innovation,” explains Dr Kodama, while discussing their investigations into these changing trends and the results of which were made available online on December 27, 2022, and published in volume 28 issue 3 of the journal Drug Discovery Today on March 1, 2023.
Their research suggests that the knowledge necessary for breakthrough innovation in drug discovery is more often than not obtained through alliance networks.
Over the past decade, large research-based pharmaceutical companies have used research collaborations, innovation incubators, academic centres of excellence, public-private partnerships, mergers and acquisitions (M&As), drug licensing, and corporate venture capital funds as typical methods for external innovation.
The researchers now aim to define the changes in the network structure and nature of such alliances that have occurred over the past decade to provide future strategic insights for industry and academic players involved in drug discovery.
Using data from the Cortellis Competitive Intelligence database, the researchers identified nearly 50,000 deals of various kinds related to pharmaceutical R&D across pharmaceutical, digital health software, animal drug, and medical device companies to uncover trends in the creation of new drugs for human use.
They also studied the trends of 13 of the largest pharmaceutical companies with annual revenues of more than $10 billion, who saw an improvement in their CAGR (compound annual growth rate) since 2015.
The researchers noticed that the rising CAGR correlated to a significant change in M&A-related deals after 2015, indicating that M&A-related deals drive revenue growth for large pharmaceutical companies.
Furthermore, the number of organizations involved in interorganisational deals has been increasing yearly from 2012 to 2021. Although the number of organizations involved and the number of deals may be increasing, the density of the deal networks is decreasing annually, suggesting that networks are becoming more non-cohesive.
The concentration of business relationships between organizations of certain areas in the network changed to dispersion around 2015, and new networks connecting different groups started to form after 2017.
These trends are an important illustration of how the industry landscape is gradually evolving away from the traditional network in which large pharmaceutical companies drove drug discovery output. Now, interorganisational deals among more diverse players have become active and are driving R&D productivity for startups in biotechnology and pharmaceuticals.
A clear increase in the number of academia-owned spinouts of advanced technology and expansion of investment in start-ups is a positive sign. The emergence of new chemical modalities, such as biologics, oligonucleotides, and peptides that differ from traditional small molecule drug discovery, indicate remarkable changes that have taken place over the past two decades.
The trend of increased financing for start-up companies in personalized drug development is beneficial for patent creation and will positively impact innovation creation in the coming years.
“The presence of academia to support the technologies of these start-ups is becoming very important, and government and private support and investment in this area are boosting innovation. Our study shows that such medium- and long-term support may ultimately benefit the health and well-being of humankind,” Dr Kodama noted.
Nigeria’s Maternal Mortality Ratio Now 814 per 100,000—Ogunrinde
By Adedapo Adesanya
The Paediatric Association of Nigeria (PAN) has said that the nation is losing its medical personnel to better-organised global settings, leaving the remaining healthcare workers in government-owned hospitals to be overstretched.
The National President of PAN, Dr Olufemi Ogunrinde, said at the opening ceremony of the association’s four-day annual general meeting and scientific conference in Akure themed Optimising Child Healthcare In Nigeria Despite Current Socio-Economic Challenges, noting that “available data shows that the country has less than one doctor to 3,000 patients, while there are 1.5 nurses to 1,000 patients.”
Dr Ogunrinde said Nigeria’s maternal mortality ratio is now 814 per 100,000 “and is closely linked to adverse neonatal outcomes with pervasive poverty and the stranglehold of communicable diseases.
“We are almost at the halfway point, at least in terms of time, to the 2030 Agenda for Sustainable Development.
“Despite our abundant quality human and natural resources, we have, as a nation, continued to make slow progress in actualising the Sustainable Development Goals, especially as pertain to our children and the youths.
“This has affected us so much that our country has continued to fare poorly in virtually all indices of health.
“Yes, we have made some gains in the health sector over the past few years, but we have had the unfortunate title of “the poverty capital of the world” bestowed on us.
“Our under-five mortality rate continues to be in the three-digit range at 104 per 1,000 live births, and infant mortality fares better at 70 per 1,000 live births.
“Our neonatal mortality and maternal mortality rates have refused to decline significantly over the last decade, with neonatal mortality stagnating at around 35 deaths per 1,000 live births. In 2009, it was 38,” he said.
Latest News on Business Post
- Streamlining and Increasing Pharmacy Inventory Workflow January 27, 2023
- Ecobank Ellevate, Others Train Fashion Entrepreneurs in Nigeria January 27, 2023
- ALAT Urges Nigerians to Imbibe Stronger Savings, Investment Culture January 27, 2023
- Lavrov Yet to Begin Choosing between Illusions and Reality for Africa January 27, 2023
- Is Loan Financing The Best For Startups? January 27, 2023
- How to Improve the Efficacy of Your Remote Workforce January 27, 2023
- How Much Is House Rent In Abuja? Everything You Need To Know January 27, 2023
- Unlisted Securities Market Gets 0.34% Boost Thursday January 27, 2023
- Naira Crashes at Parallel Market, Gains at Official Market January 27, 2023
- Stock Market Rebounds by 0.29% as GTCO, Others Enjoy Patronage January 27, 2023